
Editor's Note: Biliary tract cancer is highly aggressive and has limited treatment options. Mutations in DNA damage repair (DDR)-related genes offer a new direction for precision treatment of advanced biliary tract cancer. At the 2026 European Society for Medical Oncology (ESMO) Congress, Dr. Changhoon Yoo from Asan Medical Center, South Korea, presented the results of the randomized Phase II OPTIMUM study (Abstract No. LBA22) in an oral presentation. The study explored the value of maintenance therapy with olaparib, with or without durvalumab, following platinum-based chemotherapy in patients with advanced biliary tract cancer harboring DDR gene mutations.
To discuss this investigator-initiated Phase II exploratory trial, Oncology Frontier invited Dr. Yoo for an exclusive interview. He shared insights into the rationale behind the study design, the identification of patient subgroups most likely to benefit, and noteworthy drug developments presented at this year’s ESMO Congress, with the aim of informing further clinical exploration of precision treatment strategies for biliary tract cancer.
01
Oncology Frontier: You presented the randomized Phase II OPTIMUM study at this year’s Congress, exploring the efficacy of maintenance olaparib, with or without durvalumab, in patients with advanced biliary tract cancer harboring DDR gene mutations. Could you briefly introduce yourself and the study to our audience?
Dr. Changhoon Yoo: My name is Changhoon Yoo, and I am a medical oncologist at Asan Medical Center in Seoul, South Korea. My clinical practice focuses on the treatment of patients with hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer.
At this year’s ESMO Congress, I presented the results of the OPTIMUM study. This was an investigator-initiated Phase II trial designed to explore efficacy signals in patients with advanced biliary tract cancer harboring DDR gene mutations. Following completion of platinum-based chemotherapy, patients received maintenance treatment with either olaparib monotherapy or olaparib in combination with durvalumab.
Overall, we did not observe additional efficacy from adding durvalumab to olaparib. Olaparib itself demonstrated durable antitumor activity, and when the data from the two treatment arms were pooled, the two-year overall survival rate was approximately 40%. This finding suggests that PARP inhibitors may have therapeutic value in this biomarker-selected patient population.
We also made an important discovery: core HRD-related mutations involving BRCA1, BRCA2, and PALB2 may serve as important predictive biomarkers for PARP inhibitor treatment in advanced biliary tract cancer. This is one of the key conclusions of our study.
02
Oncology Frontier: DDR gene mutations are relatively uncommon in biliary tract cancer. What considerations informed the decision to investigate the PARP inhibitor olaparib, combined with durvalumab, as a maintenance treatment strategy for this population?
Dr. Changhoon Yoo: DDR mutations are not common in biliary tract cancer. However, with an appropriate testing panel, approximately 30%–40% of patients may be found to harbor DDR mutations. This proportion depends to a considerable extent on how DDR alterations are defined. In our study, we used a panel comprising 26 genes to define DDR mutations. Previous observations have also suggested that patients with DDR mutations may achieve better responses to platinum-based chemotherapy.
This provided the rationale for selecting a PARP inhibitor. DDR mutations are associated with survival benefits following platinum-based chemotherapy, so we hypothesized that this patient subgroup might also benefit from PARP inhibitor treatment.
In addition, some preclinical studies have suggested that specific DDR gene mutations may enhance tumor immunogenicity. We therefore hypothesized that combining durvalumab with a PARP inhibitor might produce synergistic benefits. Since prospective evidence in this area was lacking at the time, we designed this study to investigate the hypothesis.
03
Oncology Frontier: Based on the OPTIMUM study data, which patient subgroups do you believe are most suitable for maintenance treatment with olaparib?
Dr. Changhoon Yoo: Patients with core HRD-related mutations represent the preferred population. Patients harboring these mutations may derive significant benefit from an olaparib-based regimen. In other words, patients with somatic or germline BRCA1/BRCA2 mutations, or PALB2 mutations, may benefit from PARP inhibitor treatment.
04
Oncology Frontier: Which drugs presented at this year’s Congress impressed you the most? Could you briefly explain why?
Dr. Changhoon Yoo: Two drugs particularly impressed me.
The first is tarlatamab. Results from a study of this drug in extensive-stage small cell lung cancer were released yesterday, and the regimen demonstrated the longest survival data reported to date for this patient population.
The second is ivonescimab, which is being investigated in biliary tract cancer. The relevant data will be released today. I do not yet know the detailed results, but the control arm uses the current standard-of-care regimen: gemcitabine plus cisplatin and durvalumab (GemCis plus durvalumab). I am therefore very much looking forward to seeing the results of this study.

Dr. Changhoon Yoo
Asan Medical Center, South Korea